Sep 19 2013
VTT Technical Research Centre of Finland is taking an important step toward advancing its Alzheimer's disease biomarker by collaborating with the Florida Hospital Neuroscience Institute to evaluate screening, diagnostic, and prognostic potential of the biomarker assay and utilize it to specifically target which types of precautions to take when approaching early stages of the disease.
A serum biochemical signature that predicts progression to Alzheimer's disease was previously developed by scientists from VTT and the University of Eastern Finland. As a result of the collaboration, VTT was able to develop a biomarker assay, according to the company.
Earlier this week, VTT announced partnership in a consortium focused on creating new diagnostic and bioinformatics tools for psychotic disorders with the overall objective to identify, prioritize, and evaluate multi-modal blood and neuroimaging biomarkers that have diagnostic potential for prediction and monitoring psychotic disorders and associated metabolic comorbidities.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.
New comprehensive report on pediatric long COVID symptoms published